151 related articles for article (PubMed ID: 29344385)
1. Improving attendance to genetic counselling services for gynaecological oncology patients.
Pokharel HP; Hacker NF; Andrews L
Gynecol Oncol Res Pract; 2018; 5():2. PubMed ID: 29344385
[TBL] [Abstract][Full Text] [Related]
2. Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre.
Burling MJ; Gamet K; Eva L; Tan AL
Aust N Z J Obstet Gynaecol; 2019 Jun; 59(3):444-449. PubMed ID: 30883681
[TBL] [Abstract][Full Text] [Related]
3. Changing patterns of referrals and outcomes of genetic participation in gynaecological-oncology multidisciplinary care.
Pokharel HP; Hacker NF; Andrews L
Aust N Z J Obstet Gynaecol; 2016 Dec; 56(6):633-638. PubMed ID: 27530527
[TBL] [Abstract][Full Text] [Related]
4. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing.
Cohen PA; Nichols CB; Schofield L; Van Der Werf S; Pachter N
Int J Gynecol Cancer; 2016 Jun; 26(5):892-7. PubMed ID: 27051053
[TBL] [Abstract][Full Text] [Related]
5. Assessment of genetic referrals and outcomes for women with triple negative breast cancer in regional cancer centres in Australia.
Hallenstein LG; Sorensen C; Hodgson L; Wen S; Westhuyzen J; Hansen C; Last ATJ; Amalaseelan JV; Salindera S; Ross W; Spigelman AD; Shakespeare TP; Aherne NJ
Hered Cancer Clin Pract; 2021 Feb; 19(1):19. PubMed ID: 33637119
[TBL] [Abstract][Full Text] [Related]
6. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
Kentwell M; Dow E; Antill Y; Wrede CD; McNally O; Higgs E; Hamilton A; Ananda S; Lindeman GJ; Scott CL
Gynecol Oncol; 2017 Apr; 145(1):130-136. PubMed ID: 28162234
[TBL] [Abstract][Full Text] [Related]
7. Adherence to guidelines for the referral of patients with colorectal cancer and abnormal tumour tissue testing for assessment of Lynch syndrome.
Han J; Spigelman AD
ANZ J Surg; 2019 Oct; 89(10):1281-1285. PubMed ID: 30856687
[TBL] [Abstract][Full Text] [Related]
8.
Kansu B; Gardner J; Price-Tate R; Murch O; Murray A
J Obstet Gynaecol; 2021 Aug; 41(6):962-965. PubMed ID: 33228436
[TBL] [Abstract][Full Text] [Related]
9. Hereditary gynaecologic cancers in Nepal: a proposed model of care to serve high risk populations in developing countries.
Pokharel HP; Hacker NF; Andrews L
Hered Cancer Clin Pract; 2017; 15():12. PubMed ID: 28936272
[TBL] [Abstract][Full Text] [Related]
10. Referral of Ovarian Cancer Patients for Genetic Counselling by Oncologists: Need for Improvement.
Ricci MT; Sciallero S; Mammoliti S; Gismondi V; Franiuk M; Bruzzi P; Varesco L
Public Health Genomics; 2015; 18(4):225-32. PubMed ID: 26111740
[TBL] [Abstract][Full Text] [Related]
11. Patterns of referral and uptake of BReast CAncer (BRCA) gene testing of eligible women with ovarian cancer in New Zealand.
Fraser K; Tan AL; Innes C; Stephens R; Tristram A; Petrich S; Lintott C; Sykes PH; Gamet K; Christian A; Simcock B
N Z Med J; 2019 Feb; 132(1490):26-35. PubMed ID: 30789886
[TBL] [Abstract][Full Text] [Related]
12. Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions.
Wilson BJ; Torrance N; Mollison J; Wordsworth S; Gray JR; Haites NE; Grant A; Campbell MK; Miedyzbrodzka Z; Clarke A; Watson MS; Douglas A
Health Technol Assess; 2005 Feb; 9(3):iii-iv, 1-126. PubMed ID: 15694064
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
14. Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
McCuaig JM; Care M; Ferguson SE; Kim RH; Stockley TL; Metcalfe KA
Gynecol Oncol; 2020 Sep; 158(3):747-753. PubMed ID: 32674931
[TBL] [Abstract][Full Text] [Related]
15.
Piedimonte S; Power J; Foulkes WD; Weber E; Palma L; Schiavi A; Ambrosio E; Konci R; Gilbert L; Jardon K; Baret L; Zeng X
Int J Gynecol Cancer; 2020 Nov; 30(11):1757-1761. PubMed ID: 32759180
[TBL] [Abstract][Full Text] [Related]
16. Uptake of testing for germline
Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
[TBL] [Abstract][Full Text] [Related]
17. Direct Genetics Referral Pathway for High-Grade Serous Ovarian Cancer Patients: The "Opt-Out" Process.
McGee J; Peart TM; Foley N; Bertrand M; Prefontaine M; Sugimoto A; Ettler H; Welch S; Panabaker K
J Oncol; 2019; 2019():6029097. PubMed ID: 31061661
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
[TBL] [Abstract][Full Text] [Related]
19. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
